Source link : https://www.newshealth.biz/health-news/targeted-combination-shows-promise-in-metastatic-kidney-cancer/
LOUISVILLE, Ky. — More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug combination, which held disease progression at bay for 2 years, a small multicenter clinical study showed. Frontline treatment with pazopanib (Votrient) plus bevacizumab (Avastin) led to an objective response rate (ORR) of 54.9% and a 12-month […]
Author : News Health
Publish date : 2024-11-13 21:06:54
Copyright for syndicated content belongs to the linked Source.